Loading clinical trials...
Loading clinical trials...
This study will evaluate the efficacy of BGG492 in reducing the sensitivity to flashing lights of patients with photosensitive epilepsy, using EEG as a readout.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Novartis Pharmaceuticals
NCT03790137 · Photosensitive Epilepsy
NCT03686033 · Photosensitive Epilepsy
NCT03239691 · Photosensitive Epilepsy
NCT00609245 · Photosensitive Epilepsy
Novartis Investigator Site
Bielefeld
Novartis Investigator Site
Kehl-Kork
Novartis Investigator Site
Kiel
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions